RATIONALE: The serotonin 1(B/D) (5-HT1(B/D)) receptor has shown potential as a target for decreasing aggression. The 5-HT1(B/D) agonist zolmitriptan's ability to reduce aggressive behavior in humans and its interaction with the well-known aggression-enhancing drug alcohol were examined. OBJECTIVES: Our objective was to investigate zolmitriptan's potential to modify human aggression in a laboratory paradigm across a range of alcohol doses. Alcohol has been consistently associated with aggression and violence, thus we hoped to expand current understanding of alcohol's role in aggressive behavior via manipulation of the serotonin (5-HT) system. METHODS: Eleven social drinkers, seven male, were recruited to participate in a research study lasting 3-4 weeks. Aggression was measured using the point-subtraction aggression paradigm (PSAP), a laboratory model widely used in human aggression studies. Subjects were administered 5-mg zolmitriptan and placebo capsules along with alcohol doses of 0.0, 0.4 and 0.8 g/kg in a within-subject, counterbalanced dosing design. Data were analyzed as the ratio of aggressive/monetary-earning responses, to account for possible changes in overall motor function due to alcohol. RESULTS: There was a significant alcohol by zolmitriptan interaction on the aggressive/monetary response ratio. Specifically, compared to placebo, zolmitriptan decreased the aggressive/monetary ratio at the 0.4- and 0.8-g/kg alcohol doses. CONCLUSIONS: A 5-mg dose of zolmitriptan effectively reduced alcohol-related aggression in an acute dosing protocol, demonstrating an interaction of 5-HT and alcohol in human aggressive behavior.
RATIONALE: The serotonin 1(B/D) (5-HT1(B/D)) receptor has shown potential as a target for decreasing aggression. The 5-HT1(B/D) agonist zolmitriptan's ability to reduce aggressive behavior in humans and its interaction with the well-known aggression-enhancing drug alcohol were examined. OBJECTIVES: Our objective was to investigate zolmitriptan's potential to modify human aggression in a laboratory paradigm across a range of alcohol doses. Alcohol has been consistently associated with aggression and violence, thus we hoped to expand current understanding of alcohol's role in aggressive behavior via manipulation of the serotonin (5-HT) system. METHODS: Eleven social drinkers, seven male, were recruited to participate in a research study lasting 3-4 weeks. Aggression was measured using the point-subtraction aggression paradigm (PSAP), a laboratory model widely used in human aggression studies. Subjects were administered 5-mg zolmitriptan and placebo capsules along with alcohol doses of 0.0, 0.4 and 0.8 g/kg in a within-subject, counterbalanced dosing design. Data were analyzed as the ratio of aggressive/monetary-earning responses, to account for possible changes in overall motor function due to alcohol. RESULTS: There was a significant alcohol by zolmitriptan interaction on the aggressive/monetary response ratio. Specifically, compared to placebo, zolmitriptan decreased the aggressive/monetary ratio at the 0.4- and 0.8-g/kg alcohol doses. CONCLUSIONS: A 5-mg dose of zolmitriptan effectively reduced alcohol-related aggression in an acute dosing protocol, demonstrating an interaction of 5-HT and alcohol in human aggressive behavior.
Authors: J Lappalainen; J C Long; M Eggert; N Ozaki; R W Robin; G L Brown; H Naukkarinen; M Virkkunen; M Linnoila; D Goldman Journal: Arch Gen Psychiatry Date: 1998-11
Authors: Antonia S New; Monte S Buchsbaum; Erin A Hazlett; Marianne Goodman; Harold W Koenigsberg; Jenni Lo; Lisa Iskander; Randall Newmark; Jesse Brand; Karen O'Flynn; Larry J Siever Journal: Psychopharmacology (Berl) Date: 2004-05-25 Impact factor: 4.530
Authors: Samet Kose; Joel L Steinberg; F Gerard Moeller; Joshua L Gowin; Edward Zuniga; Zahra N Kamdar; Joy M Schmitz; Scott D Lane Journal: Behav Neurosci Date: 2015-02-09 Impact factor: 1.912
Authors: Klaus A Miczek; Joseph F DeBold; Lara S Hwa; Emily L Newman; Rosa M M de Almeida Journal: Ann N Y Acad Sci Date: 2015-08-18 Impact factor: 5.691
Authors: Joshua L Gowin; Charles E Green; Joseph L Alcorn; Alan C Swann; F Gerard Moeller; Scott D Lane Journal: Psychopharmacology (Berl) Date: 2013-02-01 Impact factor: 4.530
Authors: E B De Sousa Fernandes Perna; E L Theunissen; K P C Kuypers; S W Toennes; J G Ramaekers Journal: Psychopharmacology (Berl) Date: 2016-07-15 Impact factor: 4.530